The purpose-built microbiome process development laboratories in a new dedicated building creates capacity for as many as 45 process development scientists at its Gainesville, FL site.
As part of this expansion of process development and early clinical GMP capacity in the U.S., Arranta Bio is now executing the next phase of expansion of the facility, which will include three GMP drug substance suites and a GMP drug product suite with flexible capacity to meet a range of clinical supply needs. This capacity will be installed and operational by the end of 2020.
Mark Bamforth, President and CEO at Arranta Bio, said, "As an essential business, we are pleased that we have been able to safely continue our work to support clients while expanding to meet longer-term needs during this challenging period. We previously announced a $100M investment in building capacity to support microbiome pioneers. In addition to our expansion in Florida, we have maintained progress on our late stage clinical/commercial facility build-out in Watertown, Massachusetts, which is on schedule to be completed in Q4 of 2020. We are grateful to all of our employees and contractors who have safely kept our plans on track as we build the best-in-class microbiome CDMO."